Medline ® Abstract for Reference 83
of 'Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer'
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
Emens LA, Braiteh FS, Cassier P, et al
American Association for Cancer Research 106th Annual Meeting . 2015;Philadelphia, PA